Drugs / Omega-3-acid ethyl esters 90
Omega-3-acid ethyl esters 90
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT01350973 | Nov 2009 → Dec 2010 | hypertriglyceridemia | Takeda | Completed | Met primary |
| Phase 3 | NCT01350999 | Nov 2009 → Jan 2011 | hypertriglyceridemia | Takeda | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00296153 Comparator | Feb → Nov 2006 | HIV infectious disease, ischemic disease | Pronova BioPharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omega-3-acid ethyl esters 90 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01350999 ↗ |
| Known as | Omacor | “Based on the above rationale it is expected that Omacor (Omega-3-acid ethyl ester 90) will have positive effects on risk factors related to Ischemic Heart Disease in HIV...” NCT00296153 ↗ |
| Known as | Omega-3-acid ethyl ester 90 | “Based on the above rationale it is expected that Omacor (Omega-3-acid ethyl ester 90) will have positive effects on risk factors related to Ischemic Heart Disease in HIV...” NCT00296153 ↗ |
| Known as | TAK-085 | “omega-3-acid ethyl esters 90 (TAK-085)” NCT01350999 ↗ |
| Route | Oral | “TAK-085 2 g, orally, once daily for up to 12 weeks.” NCT01350973 ↗ |